Ipilimumab and Lenalidomide in Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

February 21, 2019

Study Completion Date

February 21, 2019

Conditions
Advanced Cancers
Interventions
DRUG

Ipilimumab

"Dose Escalation Group Starting Dose: 1.5 mg by vein over 90 minutes on Day 1 of each 28 day cycle.~Dose Expansion Group Starting Dose for Ipilimumab: Maximum tolerated dose (MTD) from Dose Escalation Group."

DRUG

Lenalidomide

"Dose Escalation Group Starting Dose: 10 mg by mouth on Days 1-21 of each 28 day cycle.~Dose Expansion Group Starting Dose for Lenalidomide: Maximum tolerated dose (MTD) from Dose Escalation Group."

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT01750983 - Ipilimumab and Lenalidomide in Advanced Cancer | Biotech Hunter | Biotech Hunter